Phosphorylcholine epitope on oxidized phospholipids (PC-OxPL)

The phosphorylcholine (PC) epitope on oxidized phospholipids (OxPL) and oxidized low-density lipoprotein (OxLDL) is a prominent damage-associated molecular pattern (DAMP) that plays a critical role in the pathogenesis of cardiovascular and inflammatory diseases. In healthy cell membranes, the PC headgroup of phosphatidylcholine is typically oriented in a way that is not recognized by the immune system; however, upon oxidative stress or cell death, the PC group becomes exposed as a 'neo-epitope.' This exposed epitope is recognized by innate immune components, including C-reactive protein (CRP) and natural antibodies like IgM-EO6, which trigger pro-inflammatory cascades and macrophage uptake. In the context of atherosclerosis, the accumulation of PC-bearing OxLDL in the arterial wall leads to foam cell formation and plaque progression. Therapeutic strategies targeting this epitope, such as the monoclonal antibody PC-mAb, aim to neutralize these pro-inflammatory lipids and reduce vascular inflammation. By blocking the interaction between OxPL and scavenger receptors, these therapies seek to stabilize plaques and prevent major adverse cardiovascular events.

Other names

Phosphorylcholine neo-epitopePC-epitopeOxidized LDL phosphorylcholineOxPL-PCPC-containing oxidized phospholipids

Monoclonal antibodies or binding proteins neutralize the pro-inflammatory effects of oxidized phospholipids by masking the phosphorylcholine epitope, thereby preventing its recognition by scavenger receptors on macrophages and inhibiting the formation of foam cells. This blockade reduces the recruitment of inflammatory cells to the vascular wall and promotes the stabilization of atherosclerotic plaques.